Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712251 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
A NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis, sponsored by Venova Medical.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT06712251 is a NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis that is active but no longer recruiting, run by Venova Medical. The registered enrollment target is 20 participants, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06712251, a NA study of End Stage Renal Disease (ESRD) and Chronic Kidney Disease Requiring Hemodialysis, is active but no longer recruiting, sponsored by Venova Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
Conditions Studied
Interventions
- DEVICE Velocity pAVF System
Study Locations (5)
Texas
- Texas Research Institute - Fort Worth
- STAR Vascular - San Antonio
Alabama
- Trinity Research Group - Dothan
California
- Apex Research - Riverside
Florida
- American Access Care of Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2027-01-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712251
The ClinicalTrials.gov registry entry for NCT06712251 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (95% lower). The listed sponsor is Venova Medical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 1 intervention - of which Velocity pAVF System is the first listed.
NCT06712251 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06712251 about?
NCT06712251 is a clinical study titled "Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access". The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
What is the current status of trial NCT06712251?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-01-08. Estimated completion is 2027-01-04.
What conditions does trial NCT06712251 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease Requiring Hemodialysis.
What interventions are being tested in trial NCT06712251?
The interventions under investigation include: Velocity pAVF System (DEVICE).
Who is sponsoring clinical trial NCT06712251?
This trial is sponsored by Venova Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712251 being conducted?
This trial has 5 study locations across Alabama, California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
-
Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap
COMPLETED · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
End Stage Renal Disease (ESRD)
All registered trials for this condition
Chronic Kidney Disease Requiring Hemodialysis
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.